Go to Wolters Kluwer VitalLaw.comGo to Wolters Kluwer VitalLaw.com
VitalLaw®
  • Find answers to your questions
  • Log in to access your subscriptions
In depth. On point.
In depth. On point.
  • Home
  • Legal Directory
  • Home
  • Legal Directory
In depth. On point.
  • Articles
  • Articles
  • Law Firms
  • Law Firms
  • Organizations
  • Organizations
    • TOP STORY—Short-lived AHCA yanked by GOP without a vote
    • CONDITIONS OF PARTICIPATION—OIG REPORT: State agency properly verified corrections of nursing home deficiencies
    • FALSE CLAIMS ACT—D.S.C.: Court’s findings mixed on FCA violations
    • FEDERAL LEGISLATION NEWS—Insurance antitrust exemption reform clears House
    • HEALTH CARE REFORM—CBO REPORTS: Malpractice legislation would set limits on recoveries, lower health care cost
    • HEALTH CARE REFORM—CBO REPORTS: Revised AHCA costlier with same number of uninsured
    • PRODUCTS LIABILITY (DEVICES)—D.N.M.: Product defect and failure-to-warn claims allowed to proceed against mesh device manufacturer
    • PRODUCTS LIABILITY (DRUGS)—E.D. La.: LPLA claims alone survive in defective drug case
  • Articles
  • Articles
  • Law Firms
  • Law Firms
  • Organizations
  • Organizations

    Health Law Daily Wrap Up, FEDERAL LEGISLATION NEWS—Insurance antitrust exemption reform clears House, (Mar 24, 2017)

    Organizations Mentioned:American Hospital Association

    By Anthony H. Nguyen, J.D.

    The House passed on March 22, 2017, H.R. 372, The Competitive Health Insurance Reform Act of 2017, with a bipartisan vote of 416 to 7. The Act repeals in part the McCarran-Ferguson Act antitrust exemption for insurers, including price fixing, bid rig ...

    By Anthony H. Nguyen, J.D.

    The House passed on March 22, 2017, H.R. 372, The Competitive Health Insurance Reform Act of 2017, with a bipartisan vote of 416 to 7. The Act repeals in part the McCarran-Ferguson Act antitrust exemption for insurers, including price fixing, bid rigging, and market allocation, and retains the exemption for certain collaborative activities. A CBO report projected that the Act would have no significant net effect on the premiums that private insurers would charge for health or dental insurance and that any effect on federal revenue would be negligible.

    The report noted that health insurance premiums could be lower to the extent that enacting the bill would prevent insurers from engaging in practices currently exempted from antitrust law. On the other hand, insurers could become subject to additional litigation and thus their costs and premiums might increase. The CBO estimated that both of those effects would be small.

    The American Hospital Association had expressed concerns about the abuse of market power by large commercial insurers with the Departments of Justice and Health and Human Services previously.

    IndustryNews: NewsStory GeneralNews HealthCareReformNews FederalLegislationNews AntitrustNews HealthReformNews FedTracker HealthCare TrumpAdministrationNews

    © 2026 CCH Incorporated and its affiliates and licensors. All rights reserved.

    • Manage Cookie Preferences
    • Privacy Statement
    • Terms of Use